COmBining memantine And cholinesterase inhibitors in Lewy body dementia treatment Trial (COBALT)

联合美金刚和胆碱酯酶抑制剂治疗路易体痴呆试验（COBALT）

• 批准号: nhmrc : 1191765
• 金额: $ 121.81万
• 依托单位国家: 澳大利亚
• 项目类别: International Collaborations
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2026-12-31
• 项目状态: 未结题
• 来源: https://researchdata.edu.au/combining-memantine-and-trial-cobalt/1778607
• 关键词: COmBining; memantine; cholinesterase; inhibitors; Lewy

Many people who have been diagnosed with dementia with Lewy bodies or Parkinson’s disease dementia will be prescribed drugs known as acetylcholinesterase inhibitors (e.g. donepezil, rivastigmine, galantamine) to help with their symptoms. This research trial, known as COBALT, is designed to find out whether there is any benefit from taking the drug memantine as well. Australian and UK researchers are collaborating on this trial which will recruit eligible participants from both countries.

许多被诊断为路易体痴呆症或帕金森氏病痴呆症的人将被开出被称为乙酰胆碱酯酶抑制剂的药物(例如多奈哌齐、利瓦斯汀、加兰他明)来帮助缓解他们的症状。这项名为钴的研究试验旨在找出服用美金刚是否也有任何好处。澳大利亚和英国的研究人员正在合作进行这项试验，该试验将从两国招募合格的参与者。